348 related articles for article (PubMed ID: 25998030)
21. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.
Burton CZ; Vella L; Harvey PD; Patterson TL; Heaton RK; Twamley EW
Schizophr Res; 2013 May; 146(1-3):244-8. PubMed ID: 23507359
[TBL] [Abstract][Full Text] [Related]
22. Measurement and Treatment Research toImprove Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version.
Kaneda Y; Ohmori T; Okahisa Y; Sumiyoshi T; Pu S; Ueoka Y; Takaki M; Nakagome K; Sora I
Psychiatry Clin Neurosci; 2013 Apr; 67(3):182-8. PubMed ID: 23581870
[TBL] [Abstract][Full Text] [Related]
23. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
[TBL] [Abstract][Full Text] [Related]
24. The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery.
Mohn C; Sundet K; Rund BR
J Clin Exp Neuropsychol; 2012; 34(6):667-77. PubMed ID: 22439943
[TBL] [Abstract][Full Text] [Related]
25. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
26. The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning.
Rodriguez-Jimenez R; Dompablo M; Bagney A; Santabárbara J; Aparicio AI; Torio I; Moreno-Ortega M; Lopez-Anton R; Lobo A; Kern RS; Green MF; Jimenez-Arriero MA; Santos JL; Nuechterlein KH; Palomo T
Schizophr Res; 2015 Dec; 169(1-3):116-120. PubMed ID: 26416441
[TBL] [Abstract][Full Text] [Related]
27. Neurocognition and occupational functioning in schizophrenia spectrum disorders: The MATRICS Consensus Cognitive Battery (MCCB) and workplace assessments.
Lystad JU; Falkum E; Haaland VØ; Bull H; Evensen S; Bell MD; Ueland T
Schizophr Res; 2016 Jan; 170(1):143-9. PubMed ID: 26692347
[TBL] [Abstract][Full Text] [Related]
28. Transdiagnostic validity of the MATRICS Consensus Cognitive Battery across the autism-schizophrenia spectrum.
Kuo SS; Wojtalik JA; Mesholam-Gately RI; Keshavan MS; Eack SM
Psychol Med; 2020 Jul; 50(10):1623-1632. PubMed ID: 31298174
[TBL] [Abstract][Full Text] [Related]
29. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
[TBL] [Abstract][Full Text] [Related]
30. Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.
Luckhoff HK; Kilian S; Olivier MR; Phahladira L; Scheffler F; du Plessis S; Chiliza B; Asmal L; Emsley R
Metab Brain Dis; 2019 Apr; 34(2):469-476. PubMed ID: 30604027
[TBL] [Abstract][Full Text] [Related]
31. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
[TBL] [Abstract][Full Text] [Related]
32. A confirmatory factor analysis of the MATRICS consensus cognitive battery in severe mental illness.
Lo SB; Szuhany KL; Kredlow MA; Wolfe R; Mueser KT; McGurk SR
Schizophr Res; 2016 Aug; 175(1-3):79-84. PubMed ID: 27041675
[TBL] [Abstract][Full Text] [Related]
33. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
[TBL] [Abstract][Full Text] [Related]
34. Executive attention deficits in schizophrenia: putative mandatory and differential cognitive pathology domains in medicated schizophrenia patients.
Meiron O; Hermesh H; Katz N; Weizman A
Psychiatry Res; 2013 Aug; 209(1):1-8. PubMed ID: 23102537
[TBL] [Abstract][Full Text] [Related]
35. Cognitive course in first-episode psychosis and clinical correlates: A 4 year longitudinal study using the MATRICS Consensus Cognitive Battery.
Kenney J; Anderson-Schmidt H; Scanlon C; Arndt S; Scherz E; McInerney S; McFarland J; Byrne F; Ahmed M; Donohoe G; Hallahan B; McDonald C; Cannon DM
Schizophr Res; 2015 Dec; 169(1-3):101-108. PubMed ID: 26416442
[TBL] [Abstract][Full Text] [Related]
36. An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder.
Van Rheenen TE; Rossell SL
Bipolar Disord; 2014 May; 16(3):318-25. PubMed ID: 24119238
[TBL] [Abstract][Full Text] [Related]
37. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia.
Fervaha G; Hill C; Agid O; Takeuchi H; Foussias G; Siddiqui I; Kern RS; Remington G
Schizophr Res; 2015 Aug; 166(1-3):304-9. PubMed ID: 26004693
[TBL] [Abstract][Full Text] [Related]
38. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
39. Compensatory cognitive training for people with first-episode schizophrenia: results from a pilot randomized controlled trial.
Mendella PD; Burton CZ; Tasca GA; Roy P; St Louis L; Twamley EW
Schizophr Res; 2015 Mar; 162(1-3):108-11. PubMed ID: 25631454
[TBL] [Abstract][Full Text] [Related]
40. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study.
Smith RC; Boules S; Mattiuz S; Youssef M; Tobe RH; Sershen H; Lajtha A; Nolan K; Amiaz R; Davis JM
Schizophr Res; 2015 Oct; 168(1-2):260-6. PubMed ID: 26190299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
